secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001636282-24-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Q4 2023 net loss $63.2M; cash $339.6M; pipeline on track with SPY001 FIH H1 2024
--------------------------------------------------------------------------------

- Net loss $63.2M in Q4 2023 vs $18.8M in Q4 2022; cash $339.6M as of Dec 31, 2023.
- Raised $180M gross from private placement; cash runway into H2 2026.
- SPY001 anti-α4β7 shows 22-day half-life (3x vedolizumab); FIH studies expected H1 2024 with interim data year-end.
- SPY002 anti-TL1A candidates nominated; preclinical half-life 24 days (2-3x clinical-stage); FIH in H2 2024.
- Appointed CEO Cameron Turtle and board member Mark McKenna; name changed to Spyre Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628224000007/0001636282-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628224000007/agle-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001636282-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer